VCYT ▲ +0.8% - Veracyte, Inc.
$VCYT - Veracyte Acquires Convergent Genomics, Expanding its Urology Diagnostics Portfolio with a Urinary Tumor DNA Testing Platform
Veracyte shares rose 0.8% on news that the company has acquired Convergent Genomics, adding a urinary tumor DNA testing platform to its urology diagnostics offerings. The acquisition expands Veracyte's product portfolio in the urology space, a strategically important diagnostic segment.
14-SEP-2026 04:05 PM ET
Share this post
💬 Comments
Loading comments…
Leave a comment
